Demand for Sartorius Products is Growing
The biopharma market is the fastest-growing pharmaceutical segment. Against this backdrop, we have been investing significantly in the expansion of our production capacities in all geographies – the Americas, Europe, and Asia. We are also expanding our global presence with customers, particularly in China and the United States, by setting up Customer Interaction Centers and investing in a substantial expansion of our activities in South Korea.
After making investments of around 523 million euros worldwide in 2022, Sartorius anticipates investments in relation to sales revenue (“CAPEX ratio”) to be around 12.5 percent in fiscal 2023.